ONE Resource for Pharma & Biotech HEOR: Health Economics, Outcomes Research, Pricing, and Reimbursement
3.5K views | +0 today
Follow
ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement
Health Economics, Outcomes Research, Pricing, Reimbursement, Market Access in Pharma
Curated by Patti Peeples
Your new post is loading...
Your new post is loading...
Scooped by Patti Peeples
Scoop.it!

Canada's war on healthcare economics - National Post

Canada's war on healthcare economics - National Post | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
National Post
Canada's war on healthcare economics
National Post
On June 16, The Commonwealth Fund, a private foundation in Washington, D.C., issued a scathing report on the United States' healthcare system.
more...
No comment yet.
Rescooped by Patti Peeples from HEALTHCARE & SOCIAL MEDIA
Scoop.it!

FDA Creates Opportunities For Device Professionals With Social Media Draft Guidance

FDA Creates Opportunities For Device Professionals With Social Media Draft Guidance | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it

After nearly five years in the planning, the FDA released the initial draft on character-restricted social media platform messaging (essentially Twitter).

As usual, it’s a big hot mess for marketing communications, regulatory and legal affairs professionals within medical device and pharmaceutical companies.

The draft of the proposed FDA Internet/Social Media Platform Policy for Prescription Drugs and Medical Devices would require that pharmaceutical and medical device manufacturers be able to both ‘make a product benefit claim’ and ‘incorporate risk information’ in the 140 character space limitation on Twitter.

Just how does a company wordsmith a constructive message in such few words?

“Micro Writing.”

Since the very nature of social media is to establish engagement with consumers in a timely manner, responsible drug and medical device companies need to make the messaging informative and meaningful within the 140 character limitation.  

To do that, they need to take their current technical writers, marketing communication, sales and marketing experts, and task them with the creation of condensed advertising directives that can borrow from other industries to reach an internet-savvy medical consumer.

While it is hoped that patients would continue to seek out competent medical advice on any health issue, the truth is, more and more of us start with the Internet for researching medical and health issues. And if peer-reviewed sites like WebMD, NIH.gov, and disease or condition or treatment specific websites are relatively informative, then character-restricted sites like Twitter are the clown car equivalent of trying to pack a ton of content into a limited space.

If you have never composed a Twitter message (tweet), it may be demonstrative to know that THIS sentence is exactly 140 characters in length.

Not a ton of words to convey to a patient or physician a message that could be life saving. The sentence above has no url or website link and minimum digital real estate to incorporate risk information, contact website, phone number or email address. 
What if the original message is “re-tweeted” by a patient, company sales rep, or other individual:  Is the pharmaceutical or medical device manufacturer responsible for the chain of tweets after the social media train has proverbially left the station? Will regulatory and legal affairs be required to pore over each tweet and each reply? 

The two examples (for non-existent companies) in the draft that FDA published last was indeed well under the 140 character limitation: 
Example 1
Headhurtz 
www.headhurtz.com 
For severe headache from traumatic brain injury

Example 2
NoFocus for mild to moderate memory loss; may cause seizures in patients with a seizure disorder www.nofocus.com/risk

Will 140 characters of information actually help patients or drive business to healthcare-centric companies? Or is the life expectancy of a tweet so finite with so many legal, regulatory and potentially social media blunder risks that companies will say, “Thanks, but no thanks” to another layer of compliance? Or will this new media outlet for pharma and medical companies drive traffic away from Twitter with the addition of more and more sponsored advertising?

These are questions that are yet to be answered, but there might be an effect in terms of the skills that companies look for when hiring marketing, sales and communications professionals in the device industry. These professionals can now add to the ranks of the meager number of professionals that claim they have "micro writing" skills. 

As of June 19, there were exactly 14 people in all of LinkedIn in the entire United States in ALL industries that listed “micro writing” in “Skills and Expertise” on their LinkedIn profiles. A search on the job consolidator site “Indeed.com” didn’t reveal a single job description with the phrase “micro writing” nor did a review of 300,000 medical device resumes.

With the proposed legislation in the comment and review stage, that is going to likely change.

In the medical device, life sciences and pharmaceutical industries, the phrase “micro writing” will be seen in at least as a minor requirement in more and more job descriptions, resumes and professional capability summaries. Once you have the experience complying with the FDA Social Media requirements, it certainly merits a brief mention.

Be the first on your block to add “Micro Writing” to your LinkedIn profile and resume. While it’s a small area in terms of your professional capabilities, the phrase “social media” didn’t come into common use until a decade ago. Who knows? Maybe micro writing will be a new trend – FDA regulation and all.

 


Via Plus91, Lionel Reichardt / le Pharmageek
Patti Peeples's insight:

FDA Creates Opportunities For Device Professionals With Social Media Draft Guid... | http://sco.lt/...

more...
No comment yet.
Rescooped by Patti Peeples from PATIENT EMPOWERMENT & E-PATIENT
Scoop.it!

Wolters Kluwer | Press | News | Survey: Americans Want Greater Control Over Their Own Healthcare

Wolters Kluwer | Press | News | Survey: Americans Want Greater Control Over Their Own Healthcare | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Wolters Kluwer is a market-leading global information services and publishing company focused on professionals.

(December 12, 2012)  — 

Philadelphia, PA (December 12, 2012) – According to a new Wolters Kluwer Health survey, 80 percent of consumers believe the greater “consumerization” of healthcare – or the trend of individuals taking a greater and more active role in their own healthcare – is positive for Americans. Survey data suggests many Americans feel that a greater role in their care is not only good, but necessary, with 86 percent of consumers reporting that they feel they have to take a more proactive role in managing their own healthcare in order to ensure better quality of care.

 

Most consumers also say they feel prepared to take on a greater role in managing their own healthcare, with 76 percent reporting that they have the information and tools to take a more proactive role in healthcare decisions ranging from choosing healthcare providers to researching treatment options. Despite feeling prepared, only 19 percent report that they have their own electronic Personal Health Record (PHR).

[..]

“With greater responsibility placed on patients to take a role in their own care, it’s essential that consumers have access to evidence-based tools and resources to make informed decisions about their care in partnership with their healthcare providers,” said Dr. Linda Peitzman, Chief Medical Officer, Wolters Kluwer Health. “Access to research-based medical information not only can positively impact quality of care, but it also can lead to improved doctor-patient communication and relationships.”

Survey findings showed that the notion of the “patient experience” is also gaining significance for many Americans. Three in ten adults (30 percent) want their patient experience to be the same as any other customer experience they have – such as shopping, hotel and travel experiences – complete with choices and control.

[..]


See report here

 


Via rob halkes, Lionel Reichardt / le Pharmageek
more...
rob halkes's curator insight, July 8, 2014 6:19 AM

Already at the end of 2012 this survey was completed about the consumerization of health care. See the report here .

Now, in 2014, we can state that the trend is persevering.

Ehealth is now no more option, it is a must tp adapt to patients' wishes!

Rescooped by Patti Peeples from Analytics & Social media impact on Healthcare
Scoop.it!

JAMA report looks at what drives healthcare analytics | Vital Signs | The healthcare business blog from Modern Healthcare

JAMA report looks at what drives healthcare analytics | Vital Signs | The healthcare business blog from Modern Healthcare | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it

The big hope for proponents of computer-enabled predictive analytics in healthcare is to one day see it in widespread use, at the point of care, in actionable form, to aid in real-time clinical decisionmaking.

But broad use implementation of eHPA is still in its infancy, say the authors of “Implementing Electronic Health Care Predictive Analytics: Considerations and Challenges. ”

Their piece is one of a series of articles on various permutations of Big Data in the current issue of the healthcare policy journal Health Affairs.

“The term infancy is relative,” says the article's co-author Bin Xie, health services research manager with PCCI, a Dallas-based not-for-profit corporation spun out of the healthcare data analytics work done at Parkland Health & Hospital System. 

The decades-old Framingham risk model for cardiovascular events and the APACHE II scoring systems to gauge the acuity of ICU patients are both well known examples of predictive analytics systems, the authors point out. 

But very few risk prediction models targeting hospital readmissions had been incorporated into an electronic health record system for easy use and reference, according to a 2011 survey report, published in the Journal of the American Medical Association and cited in the Health Affairs article.

“There are already many implementations across many hospitals in the country and across the world,” Xie adds in an interview. “It could grow into a big, giant adult, so, when we compare it to its potential, it's still in its infancy.”

“We think in five to 10 years, it could really become a big thing in healthcare, especially when we address the difficulty of containing costs and improving the quality of care and the challenge of the growth in the number of senior citizens,” he said.

Just as government penalties for hospital readmissions captured the attention of many early implementers of eHPA efforts, “payment reform is one essential piece to drive this growth” in the future, Xie said.

Predictive analytics has four component parts, according to the authors—acquiring data, validating the risk-prediction model, applying it in a real-world setting and scaling up the model for broader use in a healthcare system. Their article focused on the latter two and the challenges of bringing them to fruition.

Among those challenges are setting up an appropriate oversight mechanism with the right balance between enough control to keep the program operating properly and also affording it enough breathing room to grow and respond to daily events, the authors said. Another is stakeholder engagement, which includes patient consent, particularly when the risk models are still in the early stages of development. 

“The first time you go out and experiment, you do need a rigorous framework of the patient's right to know, just as you do in research study,” Xie said. 

Other issues that data analytics program planners must address are data quality assurance, patient privacy protections, interoperability of the technology platform and transparency of the risk model. 

“Whenever possible, clinicians, in particular, need to be able to 'see into' a risk-prediction model and understand how it arrived at a certain prediction,” the authors advise.  Transparency builds needed trust in the model, and it might encourage “crowd sourcing” to improve the model or expand its use to other organizations or settings.

Follow Joseph Conn on Twitter: @MHJConn


Via Chaturika Jayadewa
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

CBPartners Invited to Lead Workshop on Orphan Disease Drug Access and ... - PR Web (press release)

CBPartners Invited to Lead Workshop on Orphan Disease Drug Access and ...
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Health Reimbursement Arrangements FAQs

Health Reimbursement Arrangements FAQs | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Check out these frequently asked questions (FAQs) about Health Reimbursement Arrangements (HRAs)
Patti Peeples's insight:

One of the most important considerations for employers as they prepare to transition to a defined contribution health plan is the design of the underlying Health Reimbursement Arrangement (HRA). Here is a guide with answers to some frequently asked questions (FAQs) on HRAs. 

more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

The Week in Review: Top Stories in Outcomes Research, Market Access and ... - DigitalJournal.com (press release)

The Week in Review: Top Stories in Outcomes Research, Market Access and ...
Patti Peeples's insight:

See what's hot in health economics, outcomes research, market access, pricing

more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Policy experts, health care leaders offer landmark roadmap for better ...

Policy experts, health care leaders offer landmark roadmap for better ... | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
UC Berkeley's Richard Scheffler, Distinguished Professor of Health Economics and Public Policy and director of the Petris Center on HealthCare Markets and Consumer Welfare, and Liora Bowers, director of Health Policy ...
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

PatientsLikeMe Receives $1.9M To Create Patient Outcomes Platform

PatientsLikeMe Receives $1.9M To Create Patient Outcomes Platform | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
PatientsLikeMe has received $1.9 million from the Robert Wood Johnson Foundation to create an open-source platform for developing patient-centered health outcome measures. The platform would let patients offer feedback on measures.
Patti Peeples's insight:

Love this company....

more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Abacus International Expands Annual Partnership With HealthEconomics.Com - PR Web (press release)

Abacus International Expands Annual Partnership With HealthEconomics.Com - PR Web (press release) | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
PR Web (press release) Abacus International Expands Annual Partnership With HealthEconomics.Com PR Web (press release) HealthEconomics.Com is pleased to announce their continuing partnership with Abacus International, specialists in health...
Patti Peeples's insight:

Welcome Abacus International, leaders in health economics, reimbursement, outcomes research, and market access for pharma, biotech, and medical device.

more...
No comment yet.
Rescooped by Patti Peeples from Veille Pharma
Scoop.it!

Top digital pharma marketing trends (Part II)

Top digital pharma marketing trends (Part II) | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Digital marketing is evolving and changing day to day.  What was true yesterday is not necessarily true today plus the hype around digital marketing trends often is bigger than the reality of ROI. ...

Via Alexandre DUBOIS
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

JAMA journal quietly replaces diabetes drug commentary after learning co-author is working for drugmaker

JAMA journal quietly replaces diabetes drug commentary after learning co-author is working for drugmaker | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
JAMA Internal Medicine has replaced a commentary they published last week on the risks of two diabetes drugs, but you wouldn't know the new version was a replacement. One change is a correction abo...
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Docs to pharma marketers: you're not getting it - Medical Marketing and Media

Docs to pharma marketers: you're not getting it - Medical Marketing and Media | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Docs to pharma marketers: you're not getting it Medical Marketing and Media Safirstein said the bigger issue is that “Pharma has to find a way to insert its way into doctor's lives,” and current efforts tend to be a mix of inefficient old-school...
more...
Patti Peeples's comment, March 8, 2013 8:21 AM
I was at this conference ePharma 2013 in NYC, and I was simply astonished at how much effort pharma is putting into MD/Consumer promotion when they are no longer the decision-makers. Old school, for sure! That's why HealthEconomics.Com is at the cutting edge of talking to payers.
Scooped by Patti Peeples
Scoop.it!

European Pharma Policy Reaches "New Level of Timidity" - PharmExec.com (blog)

European Pharma Policy Reaches "New Level of Timidity" PharmExec.com (blog) A long-heralded document portentously entitled “Pharmaceutical industry: a strategic sector for the European economy,” and supposedly initiating a new start in long-term...
more...
No comment yet.
Rescooped by Patti Peeples from Analytics & Social media impact on Healthcare
Scoop.it!

Big Hitters in Health: Social, HCP Comms and Big Data

Big Hitters in Health: Social, HCP Comms and Big Data | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it

Digitally Sick are back and have taken the opportunity to look at the three big hitters for digital health in 2014: Social. HCP communications and big data (with the exception of mobile health which needs a pod of it's own).

 

Social media is now almost passé but over the last decade has revolutionised all aspects of pharma communications from patient support to clinical trials. In 2014 we are still struggling with how we should communicate with HCP's and finally big data, or data, is now the most exciting frontier in healthcare, what are the issues and how can this be leveraged by pharma?

 


Via Alex Butler, Chaturika Jayadewa
more...
No comment yet.
Rescooped by Patti Peeples from E-HEALTH - E-SANTE - PHARMAGEEK
Scoop.it!

10 Digital Health Trends for the Next 20 Years

The Digital Health Revolution is upon us. Here are the ten trends that will impact each and everyone of us in the coming years to help us live healthier, stronger and smarter lives, for longer.


Via Dinesh Chindarkar, Lionel Reichardt / le Pharmageek
more...
Mutuelle BonneAssurance's curator insight, July 15, 2014 8:53 AM

Wow! Super intéressant, pour peu qu'on comprenne un peu l'anglais! 

Ian Sibbald's curator insight, July 18, 2014 5:29 AM

Bit of "big picture" future-speculation and extrapolation  - thoughtful (and thought-provoking) context in a set of slides on some big trends for the next 20 years.

Alexis Meneses Arévalo's curator insight, July 21, 2014 8:49 AM

DALCAME

Scooped by Patti Peeples
Scoop.it!

Archimedes, a Leader in Healthcare Simulation is Acquired... -- PALO ALTO, Calif. and BETHESDA, Md., Jan. 8, 2014 /PRNewswire/ --

PALO ALTO, Calif. and BETHESDA, Md., Jan. 8, 2014 /PRNewswire/ -- Archimedes, a Leader in Healthcare Simulation is Acquired by Evidera, a Symphony Technology Group Company.
Patti Peeples's insight:

Great new acquisition, as long as Archimedes' creativity can be maintained.  Should expand Evidera's capabilities for innovative trial design to ensure optimized market access.

more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

HealthEconomics.Com presents HE-Artists

HealthEconomics.Com presents HE-Artists | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Is this YOU? Looking 4 those work in/around #HEOR /Payer Marketing who R creative, have intrsting hobbies http://t.co/AufEgpTLp3 #pharma
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Connected Health, Reimbursement, and the Law of Unintended ...

Connected Health, Reimbursement, and the Law of Unintended ... | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
In a payment system where Medicare pays hospitals a flat rate per case for inpatient hospital care, an unintended consequence of diagnosis-related group (DRG) reimbursement was to incentivize hospitals to decrease length ...
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

HealthEconomics.Com Launches New Web Series: HE-Artists - DigitalJournal.com (press release)

HealthEconomics.Com Launches New Web Series: HE-Artists DigitalJournal.com (press release) To strengthen the virtual community of Health Economists and create deeper connections with its audience of 20,000 healthcare researchers worldwide,...
more...
Patti Peeples's comment, March 11, 2013 8:49 AM
Please submit your name if you create art, have an interesting hobby, or volunteer for a special cause that you'd like to share. Let us get to know you!
Scooped by Patti Peeples
Scoop.it!

HealthEconomics.Com Launches Blog for Health Economics and Outcomes ... - Virtual-Strategy Magazine (press release)

HealthEconomics.Com Launches Blog for Health Economics and Outcomes ... - Virtual-Strategy Magazine (press release) | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
HealthEconomics.Com Launches Blog for Health Economics and Outcomes ...
more...
Patti Peeples's comment, March 11, 2013 8:49 AM
Looking for Guest Bloggers...submit to me on tHEORetically Speaking blog
Scooped by Patti Peeples
Scoop.it!

Research and Markets: Russia Pricing and Reimbursement | Business Wire

Research and Markets: Russia Pricing and Reimbursement | Business Wire | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Research and Markets (http://www.researchandmarkets.com/research/hxf89d/russia_pricing) has announced the addition of the "Russia Pricing and Rei (Research and Markets: Russia Pricing and Reimbursement http://t.co/az5JCiB6iU)...
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

As Pinterest audience rises to 15% of Internet users, are healthcare and pharma presence growing too? | E-marketing knowledge & principles

As Pinterest audience rises to 15% of Internet users, are healthcare and pharma presence growing too? | E-marketing knowledge & principles | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
As Pinterest user audience growth rivals Twitter, are healthcare and pharmaceutical companies increasing their presence? (As Pinterest audience rises to 15% of Internet users, are healthcare and pharma presence growing too?
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Top digital pharma marketing trends (Part II) | Veille Pharma

Top digital pharma marketing trends (Part II) | Veille Pharma | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Digital marketing is evolving and changing day to day. What was true yesterday is not necessarily true today plus the hype around digital marketing trends often is bigger than the reality of ROI. ...
more...
No comment yet.
Scooped by Patti Peeples
Scoop.it!

Does Pharma's Innovation Difficulties Reflect Bad Leaders or Tough ... - Forbes

Does Pharma's Innovation Difficulties Reflect Bad Leaders or Tough ... - Forbes | ONE Resource for Pharma & Biotech HEOR:  Health Economics, Outcomes Research, Pricing, and Reimbursement | Scoop.it
Fort Mills Times
Does Pharma's Innovation Difficulties Reflect Bad Leaders or Tough ...
more...
No comment yet.